| Literature DB >> 32753601 |
Marcela de Oliveira1, Thiago Marcelo Ribeiro Gianeti2, Fernando Coronetti Gomes da Rocha3, Paulo Noronha Lisboa-Filho4, Marina Piacenti-Silva4.
Abstract
It is estimated that multiple sclerosis (MS) affects 35,000 Brazilians and 2.5 million individuals worldwide. Many studies have suggested a possible role of metallic elements in the etiology of MS, but their concentration in the blood of MS patients is nonetheless little investigated in Brazil. In this work, these elements were studied through Inductively Coupled Plasma Mass Spectrometry (ICP-MS), whose analysis provides a tool to quantify the concentrations of metal elements in the blood samples of individuals with neurodegenerative disorders. This study aimed to compare the concentration of metallic elements in blood samples from patients with MS and healthy individuals. Blood was collected from 30 patients with multiple sclerosis and compared with the control group. Blood samples were digested in closed vessels using a microwave and ICP-MS was used to determine the concentrations of 12 metallic elements (Ba, Be, Ca, Co, Cr, Cu, Fe, Mg, Mo, Ni, Pb and Zn). In MS patients, we observed a reduction in the concentrations of beryllium, copper, chromium, cobalt, nickel, magnesium and iron. The mean concentration of lead in blood was significantly elevated in the MS group. However, no difference was observed in the concentrations of Mo, Ba, Ca and Zn in blood samples from MS patients and the control group. According to our data, there is a possible role for the concentrations of 8 of the 12 evaluated metallic elements in multiple sclerosis. Abnormalities in transition metals levels in biological matrices have been reported in several neurological diseases.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32753601 PMCID: PMC7403292 DOI: 10.1038/s41598-020-69979-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Metallic element concentrations in patients with multiple sclerosis and control in different studies.
| Element | References | Sample type | Technical analysis | Concentration (µg/L) | ||
|---|---|---|---|---|---|---|
| CONTROL | MS | |||||
| Ba | This work | B | ICP-MS | 5.05 ± 6.43 | 3.25 ± 2.45 | 0.897 |
| Forte et al.[ | B | ICP-AES | 1.17 ± 0.54 | 1.43 ± 0.11 | NS | |
| Visconti et al.[ | S | ICP-MS | 0.69 ± 0.42 | 1.32 ± 0.54 | < 0.05* | |
| Alimonti et al.[ | S | ICP-MS | 0.59 (0.43–0.92) | 0.61 (0.44–0.81) | NS | |
| Janghorbani et al.[ | P | ICP-AES | 1.01 ± 0.01 | 1.01 ± 0.01 | NS | |
| This work | B | ICP-MS | 0.22 ± 0.013 | 0.0003 ± 0.002 | 0.000* | |
| Be | Visconti et al.[ | S | ICP-MS | 0.26 ± 0.11 | 0.23 ± 0.06 | NS |
| Alimonti et al.[ | S | ICP-MS | 0.21 (0.31–0.32) | 0.34 (0.21–0.45) | < 0.0003* | |
| Ca | This work | B | ICP-MS | 77,029.43 ± 53,013.06 | 55,716.59 ± 18,393.67 | 0.439 |
| Forte et al.[ | B | ICP-AES | 68,006 ± 10,517 | 65,410 ± 11,264 | < 0.05* | |
| Visconti et al.[ | S | ICP-AES | 65,310 ± 5,620 | 86,017 ± 11,115 | < 0.05* | |
| Alimonti et al.[ | S | ICP-AES | 64,236 (59,380–68,340) | 73,039 (68,786–76,417) | < 0.0003* | |
| Janghorbani et al.[ | P | ICP-AES | 70,400 ± 420 | 58,300 ± 550 | < 0.001* | |
| Co | This work | B | ICP-MS | 1.46 ± 0.79 | 0.0091 ± 0.0499 | 0.000* |
| Visconti et al.[ | S | ICP-MS | 0.016 ± 0.09 | 0.21 ± 0.11 | NS | |
| Alimonti et al.[ | S | ICP-MS | 0.16 (0.10–0.25) | 0.14 (0.09–0.24) | NS | |
| Cr | This work | B | ICP-MS | 38.96 ± 148.07 | 6.03 ± 8.37 | 0.001* |
| Visconti et al.[ | S | ICP-MS | 0.14 ± 0.05 | 0.36 ± 0.22 | 0.85 | |
| Alimonti et al.[ | S | ICP-MS | 0.15 (0.12–0.21) | 0.17 (0.13–0.23) | NS | |
| Janghorbani et al.[ | P | ICP-AES | 1.09 ± 0.02 | 1.17 ± 0.02 | < 0.01* | |
| Cu | This work | B | ICP-MS | 1,052.29 ± 487.05 | 721.21 ± 222.78 | 0.000* |
| Forte et al.[ | B | ICP-AES | 926 ± 144 | 1,445 ± 481 | < 0.05* | |
| Melo et al.[ | CF | ICP-MS | 8.67 ± 0.49 | 10.90 ± 1.11 | < 0.05* | |
| Visconti et al.[ | S | ICP-AES | 953 ± 75 | 1,034 ± 228 | < 0.05* | |
| Alimonti et al.[ | S | ICP-AES | 951 (808–1,073) | 940 (819–1,031) | NS | |
| Iranmanesh et al.[ | S | CAA | 110.37 ± 37.10 | 88.58 ± 19.56 | < 0.05* | |
| Sedighi et al.[ | S | AAS | 88.9 | 93.7 | 0.46 | |
| Janghorbani et al.[ | P | ICP-AES | 1.06 ± 0.02 | 1.67 ± 0.03 | < 0.001* | |
| Fe | This work | B | ICP-MS | 496,556 ± 43,797 | 424,319 ± 51,525 | 0.000* |
| Forte et al.[ | B | ICP-AES | 546,285 ± 69,705 | 482,748 ± 83,763 | < 0.05* | |
| Visconti et al.[ | S | ICP-AES | 1686 ± 547 | 1,318 ± 527 | < 0.10* | |
| Alimonti et al.[ | S | ICP-AES | 1,610 (1,228–1995) | 920 (752–1,294) | < 0.0003* | |
| Iranmanesh et al.[ | S | CAA | 103.95 ± 33.81 | 127.04 ± 34.67 | < 0.05* | |
| Janghorbani et al.[ | P | ICP-AES | 4.25 ± 0.02 | 4.13 ± 0.03 | < 0.01* | |
| Mg | This work | B | ICP-MS | 36,416 ± 4,155.48 | 27,837 ± 4,127.48 | 0.000* |
| Forte et al.[ | B | ICP-AES | 40,392 ± 5,657 | 36,784 ± 5,804 | NS | |
| Alimonti et al.[ | S | ICP-AES | 17,424 (16,501–19,086) | 18,391 (17,458–19,638) | NS | |
| Janghorbani et al.[ | P | ICP-AES | 12,330 ± 250 | 13,470 ± 330 | < 0.1* | |
| Mo | This work | B | ICP-MS | 2.03 ± 3.22 | 1.46 ± 0.72 | 0.879 |
| Forte et al.[ | B | ICP-MS | 2.94 ± 1.65 | 2.11 ± 0.83 | < 0.05* | |
| Visconti et al.[ | S | ICP-MS | 0.86 ± 0.35 | 1.45 ± 0.49 | < 0.05* | |
| Alimonti et al.[ | S | ICP-MS | 0.84 (0.58–1.22) | 1.14 (0.82–1.43) | NS | |
| Janghorbani et al.[ | P | ICP-AES | 0.08 ± 0.04 | 0.17 ± 0.06 | NS | |
| Ni | This work | B | ICP-MS | 13.34 ± 37.04 | 1.92 ± 4.43 | 0.000* |
| Visconti et al.[ | S | ICP-MS | 0.44 ± 0.35 | 1.62 ± 1.24 | < 0.05* | |
| Alimonti et al.[ | S | ICP-MS | 0.39 (0.34–0.71) | 0.81 (0.41–1.37) | < 0.0003* | |
| Janghorbani et al.[ | P | ICP-AES | 0.001 ± 0.009 | 0.016 ± 0.012 | NS | |
| Pb | This work | B | ICP-MS | 12.46 ± 3.89 | 24.55 ± 19.94 | 0.000* |
| Forte et al.[ | B | ICP-MS | 35.6 ± 20.1 | 24.3 ± 12.7 | < 0.05* | |
| Visconti et al.[ | S | ICP-MS | 0.65 ± 0.34 | 0.53 ± 0.45 | NS | |
| Alimonti et al.[ | S | ICP-MS | 0.53 (0.34–0.71) | 0.40 (0.26–0.54) | NS | |
| Aliomrani et al.[ | B | AAS | 46.1 ± 22 | 44.7 ± 25 | 0.625 | |
| Janghorbani et al.[ | P | ICP-AES | 0.94 ± 0.01 | 0.96 ± 0.02 | NS | |
| Dehghanifiroozabadi et al.[ | S | GFAAS | 33.8 ± 28.8 | 75.6 ± 9.35 | 0.003* | |
| Zn | This work | B | ICP-MS | 4,298.35 ± 623.14 | 4,270.15 ± 823.56 | 0.883 |
| Forte et al.[ | B | ICP-AES | 6,579 ± 1,015 | 5,998 ± 1,492 | < 0.05* | |
| Melo et al.[ | CF | ICP-MS | 23.5 ± 3.2 | 19.0 ± 1.9 | NS | |
| Visconti et al.[ | S | ICP-AES | 781 ± 120 | 864 ± 160 | NS | |
| Alimonti et al.[ | S | ICP-AES | 795 (703–897) | 650 (591–710) | < 0.0003* | |
| Iranmanesh et al.[ | S | CAA | 14.1 ± 3.2 | 10.9 ± 2.1 | < 0.05* | |
| Sedighi et al.[ | S | AAS | 36.7 | 40.9 | 0.25 | |
| Janghorbani et al.[ | P | ICP-AES | 288.11 ± 2.01 | 235.20 ± 2.63 | < 0.001* | |
| Pawlitzki et al.[ | S | AAS | 14.6 ± 2.3 | 12.5 ± 2.1 | < 0.05* | |
Values are reported as means ± standard deviation, and median (interquartile ranges).
B Blood, S Serum, CF Cerebrospinal Fluid, P Plasma, ICP-OES Inductively Coupled Plasma Optical Emission Spectrometry, ICP-AES Inductively Coupled Plasma Atomic Emission Spectrometry, ICP-MS Inductively Coupled Plasma Mass Spectrometry, AAS Atomic Absorption Spectrophotometer, CAA Colorimetric Auto-Analyzer, GFAAS Graphite Furnace Atomic Absorption Spectrometry, NS non-significant statistical difference.
*Significant statistical difference.
Figure 1(a) Beryllium and cobalt; (b) Chromium and nickel; (c) Copper and magnesium; (d) Iron and (e) Lead concentration levels in patients with multiple sclerosis and control group.